drugset / Trial / NCT06654193
Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury
Phase 1/2
Recruiting
70 enrolled
Hope Biosciences LLC
The University of Texas Health Science Center, Houston · collabUniversity of Alabama at Birmingham · collabUniversity of California, San Francisco · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).
Timeline
- Start
- 2026-02-01
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic HB-adMSCs | Cell therapy | — | — |